10-K: BridgeBio Pharma Reports Strong Attruby Sales, Advances Pipeline

BridgeBio Pharma, Inc. reports significant commercial uptake for Attruby and positive Phase 3 clinical trial results for multiple pipeline candidates, despite continued net losses.

Summary

• Net loss for the year ended December 31, 2025, was $732.9 million, an increase from $543.3 million in 2024.
• Total revenues, net, increased by $280.2 million to $502.1 million in 2025, driven by Attruby product sales.
• Attruby (acoramidis) generated $362.4 million in U.S. net product revenues in 2025, with 7,804 unique patient prescriptions and 1,856 prescribing healthcare professionals.
• Beyonttra (acoramidis) received approvals in Europe (February 2025), the UK (April 2025), and Japan (March 2025), contributing $105.0 million in license and services revenue and $11.4 million in royalty revenue.
• Positive Phase 3 topline results were reported for oral infigratinib in achondroplasia, meeting all primary and secondary endpoints with a mean treatment difference of +2.10 cm/year in annualized height velocity (AHV) at Week 52 (p<0.0001).
• Positive Phase 3 topline results for encaleret in Autosomal Dominant Hypocalcemia Type 1 (ADH1) showed 76% of participants achieved normalized serum and urine calcium at Week 24 (p<0.0001).
• Positive interim analysis topline results for BBP-418 in Limb-Girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9) demonstrated statistically significant and clinically meaningful improvements in biomarker and functional measures.
• Research and development expenses decreased by $54.5 million to $451.9 million in 2025, primarily due to decreased R&D activities for Attruby/Beyonttra post-approval and program reprioritization.
• Selling, general and administrative expenses increased by $242.3 million to $531.2 million in 2025, mainly due to commercial launch activities for Attruby.
• The company issued $575.0 million in 1.75% Convertible Senior Notes due 2031 in February 2025 and $632.5 million in 0.75% Convertible Senior Notes due 2033 in January 2026 (subsequent event).
• Repaid the Amended Financing Agreement term loan of $467.0 million in February 2025, incurring a $21.2 million loss on extinguishment of debt.
• Received $300.0 million in cash from a Royalty Interest Purchase and Sale Agreement in June 2025 and $500.0 million from a Funding Agreement in December 2024, both related to acoramidis royalties.
• As of December 31, 2025, cash, cash equivalents, and marketable securities totaled $587.5 million.
• The company maintains minority equity interests in GondolaBio, LLC (27.5% ownership) and BridgeBio Oncology Therapeutics, Inc. (18.2% ownership) after spinning them out in 2024.
• The U.S. Supreme Court invalidated reciprocal tariffs on February 20, 2026, but President Trump intends to use other authorities to maintain elevated tariffs, creating uncertainty for global trade.
• The company's 2027 and 2031 Convertible Senior Notes became convertible from January 1, 2026, through March 31, 2026, due to a common stock price condition being met.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this filing as highly positive due to the strong commercial performance of Attruby and Beyonttra, coupled with multiple successful Phase 3 clinical trial readouts for key pipeline candidates, significantly de-risking future growth, despite ongoing net losses and substantial debt.

Positives

• Attruby (acoramidis) achieved significant commercial uptake in the U.S., generating $362.4 million in net product revenues in 2025.
• Beyonttra (acoramidis) received regulatory approvals in Europe, the UK, and Japan, demonstrating strong early uptake in Europe with over 50% new-to-brand prescription share in Germany.
• Oral infigratinib for achondroplasia met all primary and secondary endpoints in the PROPEL 3 study, showing statistically significant improvements in annualized height velocity and body proportionality with no serious adverse events related to the drug.
• Encaleret for ADH1 achieved positive Phase 3 results in the CALIBRATE trial, demonstrating statistically significant normalization of serum and urinary calcium.
• BBP-418 for LGMD2I/R9 showed positive interim Phase 3 results, with statistically significant and clinically meaningful improvements in biomarker and functional measures and a favorable safety profile.
• The company's decentralized hub-and-spoke model has advanced multiple programs from discovery through regulatory approval and commercialization, with an average investment of less than $40.0 million to proof-of-concept data.
• Initiated a next-generation depleter program for ATTR-CM, aiming for disease reversal and potential combination therapy.
• Maintained a broad set of early-stage development programs and strategic equity investments, including PORT-77 in Phase 2a for erythropoietic protoporphyria (EPP) at GondolaBio.
• The company's internal control over financial reporting was deemed effective as of December 31, 2025.

Negatives

• Net loss increased to $732.9 million in 2025 from $543.3 million in 2024, and the company has an accumulated deficit of $3.8 billion.
• Selling, general and administrative expenses increased significantly by $242.3 million in 2025, primarily due to commercialization efforts.
• Incurred a $21.2 million loss on extinguishment of debt from the repayment of the Amended Financing Agreement term loan.
• Noncash interest expense on deferred royalty obligations increased substantially to $125.1 million in 2025 from $8.3 million in 2024.
• Net loss from equity method investments increased to $72.6 million in 2025 from $31.2 million in 2024.
• TRUSELTIQ (infigratinib) for cholangiocarcinoma had its accelerated FDA approval withdrawn in May 2023.
• The company has incurred a significant amount of debt, totaling $1.9 billion as of December 31, 2025, plus deferred royalty obligations of $866.3 million.
• The approved list price of Attruby in the United States increased from $18,759.12 for a 28-day supply in December 2025 to $19,790.00 in January 2026, which could face public scrutiny.

Risks

• The commercial success of Attruby and Beyonttra, and future product candidates, depends on market acceptance by physicians, patients, and healthcare payors.
• Ineffective sales and marketing capabilities or inability to establish/maintain third-party agreements could hinder commercial efforts.
• Profitability depends on selling enough product at competitive prices and adequate coverage/reimbursement from governmental or private third-party payors.
• Penetrating foreign markets subjects the company to additional regulatory burdens and other risks.
• Failure to comply with healthcare laws could lead to substantial penalties and adversely affect business, operations, and financial conditions.
• Healthcare legislative measures aimed at reducing costs, such as the Inflation Reduction Act (IRA) and proposed reference pricing models (GLOBE, GUARD), may materially harm product revenues and business.
• Significant competition from established pharmaceutical and biotechnology companies, as well as academic institutions, could impact market share and commercial success.
• Substantial delays in clinical trials or inability to complete them on expected timelines could occur due to various factors, including patient enrollment difficulties, adverse events, or regulatory changes.
• Results of earlier studies or clinical trials may not be predictive of future results, and initial studies may not establish adequate safety or efficacy.
• Preliminary, interim, or topline data from clinical trials may change as more patient data become available or additional analyses are conducted.
• Product candidates are still in preclinical or clinical development, which is a lengthy and expensive process with uncertain outcomes and potential for substantial delays.
• Inability to obtain regulatory approval in one or more jurisdictions for product candidates would substantially harm the business.
• Reliance on third parties for manufacturing commercial supplies and clinical trial materials poses risks if they fail to provide sufficient quantities, acceptable quality, or reasonable prices.
• If contract manufacturing facilities do not continue to meet regulatory requirements or supply demands, the business will be harmed.
• Inability to obtain and maintain sufficient intellectual property protection for products and product candidates could allow competitors to commercialize similar products.
• Patent terms may be inadequate to protect the competitive position for an adequate amount of time.
• Product liability lawsuits could cause substantial liabilities and limit commercialization.
• Substantial additional funding may be required to achieve business goals, and inability to obtain it could force delays or termination of development and commercialization efforts.
• Significant debt obligations require substantial cash flow, and insufficient cash flow could lead to default or onerous financing terms.
• Covenants and restrictions in royalty monetization agreements (Royalty Purchase Agreement, Funding Agreement) could limit operational flexibility or result in remedies against collateral.
• Future sales and issuances of common stock could result in significant dilution and cause stock price to fall.
• The market price of common stock is highly volatile and subject to various internal and external factors.
• Exposure to the risk of fraud, misconduct, or other illegal activity by employees, contractors, and partners.
• International operations expose the company to business, regulatory, political, operational, financial, tax, pricing, and economic risks.
• Failure to maintain effective disclosure controls and internal control over financial reporting could impair financial reporting accuracy and timeliness.
• Artificial intelligence presents risks including security risks to confidential information, intellectual property risks, and challenges from an uncertain regulatory environment.
• Restrictive European data protection regulations (GDPR) impose stringent requirements on data processing and cross-border transfers, increasing compliance costs and risks.
• Adverse developments affecting the financial services industry could impair access to funding and negatively impact business operations.
• Restructuring charges from corporate initiatives may not result in anticipated savings and could disrupt operations.
• Expending limited resources on particular product candidates may cause the company to fail to capitalize on more profitable opportunities.
• Adverse effects from climate change, earthquakes, disease outbreaks, or other natural disasters could disrupt operations.
• Increasing use of social media platforms presents new risks and challenges related to regulatory compliance and reputation.

Future Outlook

The company plans to pursue regulatory submissions for infigratinib (achondroplasia), BBP-418 (LGMD2I/R9), and encaleret (ADH1) in the U.S. and Europe in the first and second halves of 2026, actively preparing for worldwide commercial launches if approved. A registrational study of encaleret in chronic hypoparathyroidism and pediatric ADH1 is expected to initiate in 2026, and a study of infigratinib for hypochondroplasia in 2027. The next-generation ATTR-CM depleter program is planned to advance into the clinic in 2027-2028. The total market for ATTR therapeutic interventions is expected to grow, potentially exceeding $20.0 billion globally. The company expects to continue incurring operating and net losses for at least the next several years, with future revenue primarily from recurring net product revenue of Attruby and Beyonttra royalties.

Management Comments

• "Our achievements in 2025 demonstrate strong commercial momentum with the potential for Attruby to become a significant commercial asset over time."
• "During 2026, we expect to progress each of these programs towards anticipated approvals in the United States and Europe and are actively preparing for the worldwide commercial launches of these products, if approved."
• "We believe each of these programs has the potential to serve a significant patient population with best-in-class or first-in-class medicines."
• "Our corporate objective at BridgeBio is to develop medicines that meaningfully improve patient outcomes and thereby maximize the positive impact we can have on the quality-adjusted life-years of the patients we serve as quickly as possible."
• "We believe our decentralized hub and spoke model enables us to achieve clinical proof-of-concept with speed and efficiency, demonstrated by an average investment per program of less than $40.0 million to proof-of-concept data and less than $10.0 million to reach Investigational New Drug (IND) submission."

Industry Context

StockSavvy.ai notes that BridgeBio Pharma operates in the highly competitive biopharmaceutical industry, focusing on rare genetic diseases. The successful commercialization of Attruby positions it against established competitors like Pfizer's Vyndaqel/Vyndamax and Alnylam's vutrisiran in the ATTR-CM market. The company's pipeline, with multiple Phase 3 candidates for achondroplasia, LGMD2I/R9, and ADH1, aims to address significant unmet medical needs, potentially offering first-in-class or best-in-class therapies. The strategic spin-outs of GondolaBio and BridgeBio Oncology Therapeutics allow the company to retain exposure to a broad early-stage pipeline while focusing on its core late-stage assets. The industry faces increasing scrutiny over drug pricing and evolving regulatory landscapes, which could impact future revenues and market access.

Comparison to Industry Standards

• Attruby (acoramidis) is positioned as a next-generation oral TTR stabilizer, competing with Pfizer's Vyndaqel/Vyndamax (tafamidis) and Alnylam Pharmaceuticals' vutrisiran for ATTR-CM. Attruby's label specifying near-complete stabilization of TTR and demonstrated 42% reduction in composite all-cause mortality and recurrent cardiovascular-related hospitalization events at Month 30 suggests a competitive profile.
• Infigratinib for achondroplasia, if approved, would compete with BioMarin Pharmaceutical Inc.'s Voxzogo (vosoritide), an approved injectable therapy. BridgeBio highlights infigratinib's oral administration and dual FGFR3 signaling inhibition (MAPK and STAT1) as differentiated advantages over CNP analogs like vosoritide, which primarily inhibit MAPK signaling.
• BBP-418 for LGMD2I/R9 has the potential to be the first disease-modifying therapy, as there are currently no approved treatments for this condition, setting a new standard if successful.
• Encaleret for ADH1, if approved, would be the first targeted therapy for this condition, where current standard of care is limited to oral calcium and/or activated vitamin D supplementation, offering a significant advancement in treatment options.

Management Changes

Corporate Governance

Legal Proceedings

• Not party to any material legal proceedings as of December 31, 2025.
• May become party to legal proceedings and claims arising in the ordinary course of business in the future.

Related Party Transactions

• KKR & Co. Inc., a beneficial holder of common equity, acquired a majority ownership interest in HealthCare Royalty Management, LLC (HCRx) on July 30, 2025, making HCRx a related party.
• The Royalty Interest Purchase and Sale Agreement (June 27, 2025) was entered into with Acoramidis Royalty SPV, LP (ARS), an affiliate of HCRx, and LSI Financing Fund, LP.
• An entity owned by Neil Kumar, the company's Chief Executive Officer, is part of the third-party investor syndicate providing financing to GondolaBio, LLC.
• KKR Capital Markets LLC (KCM), an affiliate of KKR Genetic Disorder L.P. (a beneficial stockholder), received a commission of $1.8 million from the September 2023 Private Placement.

Stakeholder Impact

• **Shareholders:** Potential for increased value from successful commercialization of Attruby and pipeline approvals, but also dilution risk from future capital raises and volatility in stock price. Significant debt and losses could impact returns.
• **Patients:** Access to new, potentially best-in-class or first-in-class therapies for rare genetic diseases (ATTR-CM, achondroplasia, LGMD2I/R9, ADH1). Patient assistance programs aim to improve affordability and access.
• **Employees:** Restructuring initiatives and workforce reductions could impact job security and morale. Competitive total rewards package and professional development aim to attract and retain talent.
• **Healthcare Providers:** New treatment options for rare diseases, supported by commercialization efforts and educational activities. Potential for increased scrutiny on promotional practices.
• **Regulatory Authorities:** Ongoing interactions for pipeline approvals and compliance with evolving healthcare laws and data privacy regulations (e.g., IRA, AI Act, GDPR).

Next Steps

• Submit a New Drug Application (NDA) to the FDA and a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for infigratinib in achondroplasia in the second half of 2026.
• Submit an NDA to the FDA for encaleret in ADH1 in the first half of 2026, followed by an MAA to the EMA.
• Submit an NDA to the FDA for BBP-418 in LGMD2I/R9 in the first half of 2026.
• Initiate a registrational Phase 3 study of encaleret in adults with Chronic Hypoparathyroidism (CHP) in the summer of 2026.
• Dose the first participant in the registrational Phase 2/3 study of encaleret in pediatric ADH1 in the first quarter of 2026.
• Accelerate the development of oral infigratinib in hypochondroplasia, with proof-of-concept results expected in the second half of 2026.
• Advance the ATTR-CM depleter program into the clinic in 2027-2028, subject to successful completion of IND-enabling studies and regulatory review.
• GondolaBio intends to initiate a Phase 2b/3 clinical trial for PORT-77 in erythropoietic protoporphyria (EPP) in 2026, pending regulatory feedback.
• Continue collaborations with Bayer and Alexion to drive continued growth of Beyonttra in Europe and Japan, respectively.
• Monitor and potentially adjust operating plans based on economic conditions, inflationary pressures, regulatory changes, and commercialization progress.

Key Dates

Recommendation

BridgeBio Pharma demonstrates strong momentum with its commercial product Attruby, generating substantial revenue shortly after approval, and Beyonttra showing robust international uptake. The positive Phase 3 data for three additional late-stage candidates (infigratinib, BBP-418, encaleret) significantly de-risks the pipeline and points to multiple potential future revenue streams. While the company continues to incur net losses and carries substantial debt, these are common for a biotech in a high-growth commercialization and late-stage development phase. The strategic royalty monetization deals and recent convertible note offerings provide capital to support these initiatives. The long-term market potential for its target indications, coupled with differentiated therapies, suggests significant upside for investors willing to tolerate the inherent risks of biotech development.

Keywords

Biopharmaceutical, Genetic Diseases, ATTR-CM, Acoramidis, Attruby, Beyonttra, Achondroplasia, Infigratinib, LGMD2I/R9, BBP-418, ADH1, Encaleret, Clinical Trials, Regulatory Approval, Orphan Drug, Rare Pediatric Disease, SEC Filing, 10-K, Biotech, Drug Development, Commercialization, Convertible Notes, Royalty Monetization, Financial Performance, Risk Factors, Intellectual Property, Corporate Governance